SXTC (sxtchina.com) Net Profit

Corporate emblem and logo of China SXT Pharmaceuticals (SXTC)

China SXT Pharmaceuticals (SXTC) maintains the status of a respected brand in the Eastern medicine segment, enjoying customer trust across the Asian region. Currently, the R&D center is focused on refining herbal extract standards and upgrading packaging equipment. The business relies on a diversified pharmaceutical approach, where net profit stands at -0.01. This chart of current share prices clearly demonstrates the financial dynamics of the company.

SXTC (sxtchina.com) Company Net Income history from 07/04/2022 to 11/01/2026

Financial and market metric breakdowns for sxtchina.com (SXTC)

- price and consensus price forecast:
Stock Quotes China SXT Pharmaceuticals, Inc.|SXTC - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization SXTC|SXTC - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share China SXT Pharmaceuticals|SXTC - Company Book Value|Market-to-Book Ratio sxtchina.com|SXTC - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital China SXT Pharmaceuticals|SXTC - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital China SXT Pharmaceuticals, Inc.|SXTC - Company Aggregate Debts|Debts to Book Value SXTC|SXTC - Company Long-Term Debt|Company Short-Term Loans and Borrowings China SXT Pharmaceuticals|Quick Liquidity Indicator sxtchina.com
- net income and valuation multiples indicators:
SXTC - Net Profit
Fundamental valuation:SXTC SXT China
Flagship merchandise of SXT Pharmaceuticals

Investors must eliminate speculative risks by assessing the issuer's actual ability to generate cash flow. Delegating raw material procurement to cooperatives minimizes operating expenses for China SXT Pharmaceuticals (SXTC). The company's annual net profit captures the final gain after deducting all real-economy expenses. This metric measures the business's resilience to inflation and commodity cycles. Positive momentum confirms the reliability of the chosen outsourcing model.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Net Profit TBPH (Theravance Biopharma, Inc.)|AQST - Net Income|scPharma - Net Profit|Final Profit TECX (Tectonic Therapeutic, Inc.)|TNXP: Net Profit|EPRX - Net Financial Result|Company Net Income BioHarvest Sciences Inc.|Company Profit EXOZ (Invizyne Technologies)|Net Profit ORMP|Net Profit enterabio.com (ENTX)|MindWalk Holdings - Net Income|Final Profit ABVC|CPIX - Company Net Income|Net Financial Result Quantum BioPharma Ltd. QNTM|FGEN (FibroGen Corp) - Net Income|Company Profit TELO|Net Income RANI|SNYR (Synergy CHC Corporation) - Profit After Payment of Taxes|Net Income RLYB (Rallybio Corporation)|LEXX (lexariabioscience.com) - Final Profit|Company Net Income Pulmatrix Corp PULM|PTHL (Pheton Holdings Limited) - Profit After Tax|Aptorum - Net Profit|Final Profit LYRA (lyratherapeutics.com)|IBO: Net Profit|TNF Pharmaceuticals, Inc. (TNFA) - Net Profit|Company Net Income cbdMD Inc.|PRFX: Final Profit|Company Net Income Altamira Therapeutics (CYTO)|Net Income lipella.com LIPO|Net Profit OPTN (OptiNose)|Net Profit Pieris Pharmaceuticals Inc PIRS|Procaps Group SA - Net Profit|Petros Pharma (PTPI) - Net Income|QLI: Net Profit|Company Net Income acelyrin.com (SLRN)|Net Income TFFP